Financial reports
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
14 Apr 23
10-K
2022 FY
Annual report
27 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Completion of Acquisition or Disposition of Assets
20 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
8 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Nov 23
8-K
Voting and Support Agreement
31 Aug 23
8-K
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
22 May 23
8-K
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 May 23
Registration and prospectus
15-12G
Securities registration termination
30 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
Proxies
DEFA14A
Additional proxy soliciting materials
2 Nov 23
DEFA14A
Additional proxy soliciting materials
30 Oct 23
DEFM14A
Proxy related to merger
10 Oct 23
DEF 14A
Definitive proxy
14 Apr 23
DEF 14A
Definitive proxy
15 Apr 22
DEF 14A
Definitive proxy
16 Apr 21
DEF 14A
Definitive proxy
14 Oct 20
DEF 14A
Definitive proxy
12 Apr 19
DEF 14A
Definitive proxy
9 Apr 18
PRER14A
Preliminary revised proxy
30 Mar 18
Other
EFFECT
Notice of effectiveness
27 Nov 23
EFFECT
Notice of effectiveness
27 Nov 23
EFFECT
Notice of effectiveness
3 May 22
CORRESP
Correspondence with SEC
28 Apr 22
CORRESP
Correspondence with SEC
28 Apr 22
UPLOAD
Letter from SEC
26 Apr 22
EFFECT
Notice of effectiveness
8 Dec 21
CORRESP
Correspondence with SEC
3 Dec 21
UPLOAD
Letter from SEC
1 Dec 21
CT ORDER
Confidential treatment order
16 Sep 21
Ownership
4
STEVE ASELAGE
20 Nov 23
4
JOHN MICHAEL DUNN
20 Nov 23
4
Donald Joseph
20 Nov 23
4
Chris Schelling
20 Nov 23
4
HARRY S PALMIN
20 Nov 23
4
Jefferson E Davis
20 Nov 23
SC 13D/A
TVM Life Science Ventures VI LP
30 Mar 23
4
Adrian W Quartel
16 Mar 23
4
Bernard H Paul
16 Mar 23
4
HARRY S PALMIN
16 Mar 23